Revolutionize cancer screening
Screening for a signal shared by 50+ cancers is now possible with the Galleri test - all with a single blood draw.1
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative signal results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative signal results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Cancer screening today: Too little, too late
~70%
of cancer deaths are caused by cancers without recommended screening.2*
1 in 5
people will die from cancer, one of the leading causes of death in the U.S.3,4
*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cases
Patients deserve more
See the unseen with Galleri
The first of its kind, the Galleri test gives you the power to screen early for a signal shared by 50+ types of cancer - all with a single blood draw.1
If a cancer signal is detected, the Galleri test predicts its origin with high accuracy to help guide the next steps to diagnosis.9
Join thousands of patients and providers using Galleri
- 100,000+ tests10
- 7,100+ ordering providers10
In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with "Cancer Signal Detected" test result
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative signal results do occur.
Get started with Galleri
Leading organizations are using the Galleri test to screen for cancer early, including:
“Multi-cancer early detection tests should be added to routine cancer screening, and that's what we're doing here at Adventist Health.”
Dr. Tyler Kang
Medical Oncologist and Medical Director
Adventist Health Martin O'Neill Cancer Center
‡The PATHFINDER study was conducted with an earlier version of Galleri. Participants responding satisfied, very satisfied, or extremely satisfied to the following question: “Taking all things into account, how satisfied or dissatisfied are you with the multi-cancer early detection test?”
"I strongly believe that because of the Galleri test, the lesion was detected early and was successfully treated. Without that, we would have probably faced much more complicated therapy."
– Martin Poliak, MD, Internal Medicine
“I tell them this is a unique opportunity. We’re the only health system in this city that has availability of this blood test that can detect a shared cancer signal across 50-plus different types of cancer. It’s no cost because of a grant from our foundation. Then I ask, ‘Is this something that you’re interested in doing?’ And they always say yes.”
– Patrick McGill, MD, Executive Vice President & Chief Transformation Officer at Community Health Network
Cancer won't wait. Neither should you.
Learn more about Galleri
Learn more
To connect with GRAIL, please fill out this form.
If you are a concierge, private, or group practice provider, complete this form instead.
-
What describes you best?
-
What are you looking for?
-
Fill in the form
Health System or Provider Network
By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.
Sign up for email about the Galleri test
This form is meant for representatives of Healthcare Systems only, if you are an individual healthcare provider or patient, please use this form instead.
By submitting this form, you agree to GRAIL’s use of this information to contact you, including for marketing purposes. Please do not include any sensitive or confidential information, including health information. For more information, please refer to our privacy notice.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.
Estimated deaths per year in 2021 from American Cancer Society Cancer Facts and Figures 2021. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html.
American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html.
Leading Causes of Death https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
Market research GRAIL, Inc. data on file GA-2022-0089.
Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin. “Late/Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body. Data on file GA-2021-004.
GRAIL, Inc. Data on File GA-2022-0089.
Reddy SR, et al. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022;38(8):1285-1294. DOI: doi.org/10.1080/03007995.2022.2047536.
Schrag D, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.
GRAIL, Inc. Data on File GA-2022-0078.
Hubbell E, Clarke C, Aravanis A, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021;30:460-8. DOI: doi.org/10.1158/1055-9965.EPI-20-1134.
Schrag D, et al. Evaluation of Anxiety, Distress and Satisfaction Using a Multi-Cancer Early Detection (MCED) Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.
GRAIL, Inc. Data on File GA-2023-0109.
GRAIL, Inc. Data on File GA-2021-0072-MR.